Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Gerd-Rüdiger R BurmesterVibeke StrandAndrea Rubbert-RothHoward AmitalTatiana RaskinaAntonio Gómez-CentenoClaudia Pena-RossiLeon GervitzKarthinathan ThangaveluGregory St JohnSusan BoklageMark C GenovesePublished in: RMD open (2019)
During this OLE, there were no unexpected safety issues in patients switching from adalimumab to sarilumab monotherapy, and disease activity improved in many patients. Patients continuing sarilumab reported safety consistent with prolonged use and had sustained benefit.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- disease activity
- open label
- peritoneal dialysis
- systemic lupus erythematosus
- clinical trial
- randomized controlled trial
- patient reported outcomes
- juvenile idiopathic arthritis
- phase ii
- rheumatoid arthritis patients